Efficacy and optimal dose of coenzyme Q10 supplementation on inflammation-related biomarkers: A GRADE-assessed systematic review and updated meta-analysis of randomized controlled trials.

SCOPE:

Coenzyme Q10 (CoQ10) has become a popular nutritional supplement due to its wide range of beneficial biological effects. Previous meta-analyses showed that the attenuation of CoQ10 on inflammatory biomarkers remained controversial. This meta-analysis aimed to assess the efficacy and optimal dose of CoQ10 supplementation on inflammatory indicators in the general population.

METHODS AND RESULTS:

Databases are searched up to December 2022 resulting in 6713 articles, of which 31 were retrieved for full-text assessment and included 1517 subjects. Double-blind randomized controlled trials (RCTs) of CoQ10 supplementation were eligible if they contain C reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). CoQ10 supplementation could significantly reduce the levels of circulating CRP (

SMD:

-0.40, 95% CI.: [-0.67 to -0.13], p = 0.003), IL-6 (

SMD:

-0.67, 95% CI.: [-1.01 to -0.33], p < 0.001) and TNF-α (

SMD:

-1.06, 95% CI.: [-1.59 to -0.52], p < 0.001) and increase the concentration of circulating CoQ10.

CONCLUSION:

This meta-analysis provides evidence for CoQ10 supplementation to reduce the level of inflammatory mediators in the general population and proposes that daily supplementation of 300-400 mg CoQ10 showed superior inhibition of inflammatory factors. This article is protected by copyright. All rights reserved.